South & Central America Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The therapeutic vaccines market in South and Central America is projected to grow significantly, reaching approximately US$ 6,998.78 thousand by 2031, up from US$ 3,370.35 thousand in 2024, reflecting a compound annual growth rate (CAGR) of 11.0% from 2024 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: Brazil, Argentina, and the Rest of South and Central America. Growth in this sector is driven by a large population, improving healthcare infrastructure, and an increasing governmental emphasis on healthcare innovation. Additionally, rising healthcare expenditures and a growing demand for treatments due to the prevalence of chronic diseases further stimulate market expansion.

Market Segmentation

The therapeutic vaccines market is categorized by product type, technology, and end user:

By Product: The market includes cancer vaccines, infectious disease vaccines, and others, with cancer vaccines dominating the market share in 2024.
By Technology: The market is divided into allogenic and autologous vaccines, with allogenic vaccines holding the largest share in 2024.
By End User: The primary end users are hospitals, clinics, and others, with hospitals accounting for the largest market share in 2024.

Market Outlook

The therapeutic vaccines sector is experiencing robust investment and advancements in vaccine development, driven by the increasing global demand for innovative treatment options. There is a notable rise in clinical candidates advancing through various development stages. Innovative research and development in biotechnology are leading to the creation of advanced therapeutic vaccines targeting a range of diseases, particularly chronic conditions like cancer and newer infections.

For instance, Moderna's mRNA-4157 is currently in phase 2 trials, showing promising results in combination with checkpoint inhibitors for melanoma treatment. The therapeutic vaccine pipeline is also expanding in areas such as autoimmune diseases and infectious diseases, including HIV, HPV, and HBV infections.

Numerous companies are focusing on scientific and technical excellence to develop and launch new therapeutic vaccines. The expanding pipeline of vaccine candidates targeting diverse diseases presents significant opportunities to meet unmet medical needs. Below is a summary of the therapeutic vaccine pipeline:

|--------------|---------------------|--------------|-----------|

With numerous clinical trials underway, the market's future looks promising, offering new treatment options for patients and addressing unmet medical needs in areas where existing treatments fall short. The strong pipeline of therapeutic vaccine candidates indicates substantial growth potential for the market.

Country Insights

The therapeutic vaccines market in South and Central America includes Argentina, Brazil, and the Rest of South and Central America, with Brazil holding the largest market share in 2024. Brazil's market potential is bolstered by its large population, improving healthcare infrastructure, and a governmental focus on healthcare innovation. As of 2022, over 30 million Brazilians were aged 60 and above, a figure expected to rise to nearly 50 million by 2030, representing 24% of the population. The country faces a high incidence of chronic diseases and cancers, creating a significant health burden. According to GLOBOCAN 2020, Brazil reported 592,212 cancer cases, highlighting the need for effective therapeutic vaccines to alleviate this burden. As healthcare professionals become more familiar with personalized medicine and targeted therapies, the demand for therapeutic vaccines is anticipated to grow.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.

Product Code: BMIRE00032094

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. South & Central America Therapeutic Vaccines Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Prevalence of Chronic Conditions
- 4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
- 4.2.1 Regulatory Challenges
4.3 Market Opportunities
- 4.3.1 Extending Product Pipeline
4.4 Future Trends
- 4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - South & Central America Market Analysis

5.1 South & Central America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 South & Central America Therapeutic Vaccines Market Forecast Analysis

6. South & Central America Therapeutic Vaccines Market Analysis - by Product

6.1 Cancer Vaccine
- 6.1.1 Overview
- 6.1.2 Cancer Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 Infectious Disease Vaccine
- 6.2.1 Overview
- 6.2.2 infectious Disease Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
- 6.3.1 Overview
- 6.3.2 Others: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. South & Central America Therapeutic Vaccines Market Analysis - by Technology

7.1 Allogenic Vaccine
- 7.1.1 Overview
- 7.1.2 Allogenic Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
- 7.2.1 Overview
- 7.2.2 Autologous Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. South & Central America Therapeutic Vaccines Market Analysis - by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
- 8.2.1 Overview
- 8.2.2 Clinics: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. South & Central America Therapeutic Vaccines Market - Country Analysis

9.1 South & Central America
- 9.1.1 South & Central America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 South & Central America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 Brazil: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.2.1 Brazil: South & Central America Therapeutic Vaccines Market Share - by Product
    - 9.1.1.2.2 Brazil: South & Central America Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.2.3 Brazil: South & Central America Therapeutic Vaccines Market Share - by End User
  - 9.1.1.3 Argentina: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.3.1 Argentina: South & Central America Therapeutic Vaccines Market Share - by Product
    - 9.1.1.3.2 Argentina: South & Central America Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.3.3 Argentina: South & Central America Therapeutic Vaccines Market Share - by End User
  - 9.1.1.4 Rest of South & Central America: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.4.1 Rest of South & Central America: South & Central America Therapeutic Vaccines Market Share - by Product
    - 9.1.1.4.2 Rest of South & Central America: South & Central America Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.4.3 Rest of South & Central America: South & Central America Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Dendreon
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 BioNTech SE
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck & Co Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Amgen Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Transgene SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 THERAVECTYS SA
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 CureVac SE
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms